Deepak L Bhatt, MD, MPH
Executive Director of Interventional Cardiovascular Programs
Professor, Harvard Medical School
Brigham and Women’s Hospital, Division of Cardiovascular Medicine
This online activity will look at chronic hypercholesterolemia as a pathogenic factor in cardiovascular disease. With a focus on PCSK9- inhibitor therapy, the talk will assess clinical trials and cardiovascular outcomes against the backdrop of residual cardiovascular risk in patients on maximally tolerated statin therapy.
This activity is intended for interventional cardiologists involved in the management of patients at high risk for cardiovascular disease (CVD) due to hypercholesterolemia.
Upon the completion of this program, attendees should be able to:
- Discuss the PCSK9 inhibitor clinical trial data in the management of high-risk patients post acute coronary syndrome (ACS) and other cardiovascular events
- Review the medical economics of PCSK9 inhibition in the post-ACS patient despite the use of maximally-tolerated statin therapy
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this online activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.
NURSING CREDIT INFORMATION
This program would be beneficial for nurses involved in the management of patients at high risk for cardiovascular disease due to hypercholesterolemia.
0.5 ANCC Contact Hour
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 0.5 contact hour of continuing nursing education of RNs and APNs
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Bhatt conducts research for Abbott, Amarin, Amgen, AstraZeneca, Bayer, Boehringer lngelheim, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, ldorsia, Ironwood, lschemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi Aventis, Synaptic, and The Medicines Company.
CME content review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE content review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Chris Drury, Medical Services for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures.
2. Participate in the online activity.
3. Submit the evaluation form to Med Learning Group.
Participants will receive their certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at http://medlearninggroup.com/privacy‐policy/
RELEASE DATE: April 1, 2019
EXPIRATION DATE: April 1, 2020
Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.